Furthermore, patients with a high VS were more likely to achieve complete or partial responses, or have an inflamed tumor microenvironment in response to immunotherapy (Figure 1H,I), indicating that VS could predict immune responses to anti‐PD‐1/L1 immunotherapy. This evidence concerns the gene PDCD1 and neoplasm.